WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of TangenX® ...
For decades, therapeutic monoclonal antibody (mAb) production relied on traditional batch-based manufacturing using stainless steel systems. But as biopharmaceutical pipelines grow to meet rising ...
(MENAFN- EIN Presswire) EINPresswire/ -- The Tangential Flow Filtration market is dominated by a mix of global bioprocessing leaders and specialized filtration technology innovators. Companies are ...
Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback